Company Information

ORTIN LABORATORIES LTD.

NSE : ORTINLABBSE : 539287ISIN CODE : INE749B01020Industry : Pharmaceuticals & DrugsHouse : Private
BSE19.15-0.28 (-1.44 %)
PREV CLOSE ( ) 19.43
OPEN PRICE ( ) 19.82
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3896
TODAY'S LOW / HIGH ( )19.09 19.83
52 WK LOW / HIGH ( )16.15 30.33
NSE19.20-0.2 (-1.03 %)
PREV CLOSE( ) 19.40
OPEN PRICE ( ) 19.75
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 19.20 (300)
VOLUME 10020
TODAY'S LOW / HIGH( ) 19.10 19.95
52 WK LOW / HIGH ( )16.2 30.35
ChairmanMurali Krishna Rayaprolu
Managing DirectorS Murali Krishna Murthy
Company SecretaryDivya Purswani
Non Executive DirectorS Balaji Venkateswarlu
Pramod Dnyandeo Waghe
Shashikant Shankarrao Igave
Non Executive Independent DirectorB Gopal Reddy
Pottur Sujatha
Whole Time DirectorS Srinivas Kumar
Incorporation Year : 27-10 1986

Registered Office :

Address : D No.1-8- B 4, Ground Floor,F3 H I G, Block - 4, Street No.3,Baghlingampally Hyderabad,
Telangana-500044 .

Phone : 040-27567266 / 27562055

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,Chennai

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.